Specialty Pharmacy

The APPOINT-PNH study showed that twice-daily LNP023 (Iptacopan) helped patients with paroxysmal nocturnal hemoglobinuria control intravascular hemolysis.

The market for digital therapeutics products is expected to grow given increasing global access to smart technologies, their cost-effectiveness, and the need for patient-specific treatments.

Pharmacists were asked about their levels of burnout, drivers and symptoms of this burnout, and what steps their workplaces had taken to improve the issue.

While the demand for professionals adept in the ability to work with big data is at an all-time high, there remains a significant lack of skilled talent.

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Annual Asembia summit features insights from key opinion leaders, networking events, and continuing education sessions for pharmacists, pharmacy staff and stakeholders.

Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Omidubicel-onlv therapy aims to quicken the recovery of neutrophils and reduce the risk of infection in patients with cancer.

The Apothecary Shoppe in Utah knows patients by name, garners new business via word of mouth.

These study results are the first to demonstrate randomized evidence that a personalized neoantigen approach could be beneficial for patients with cancer.

These data support using this combination therapy as a new first-line treatment option in patients with previously untreated metastatic or unresectable BTC.

Based on the study results, investigators concluded that there is justification for a randomized clinical trial.

The Aquilino Cancer Center established the Bill Richards Center for Healing inside the same building, so patients with cancer can receive psychedelic-assisted therapy in the same location as their cancer care.

Establish procedures, including training employees, to address shortages, back-order situations.

Remote services allow unrivaled opportunities for outreach to vulnerable populations and those in rural areas.

Pharmacy professionals can bring in the right people at the right time to identify needed changes and develop an action plan.

During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.

The FDA’s temporary Guidance for 503A compounding of shortage drugs was meant to be temporary and withdrawn once COVID-19 ended.

Individuals treated with the drugs from AstraZeneca demonstrate clinically meaningful and statistically significant improvement.

Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.

Pharmacists are cited as one of the most stressed professions and a creative habit can help to improve focus, enhance productivity, and reduce stress.

Enfortumab vedotin-ejfv (Padcev, Astellas Pharma and Seagen Inc) with pembrolizumab (Keytruda, Merck) approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.

Additionally, study results show a clinically meaningful overall survival trend in the overall population among individuals with primary advanced or recurrent disease.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

This method has proven economically appealing, but further confirmation of these findings is needed, according to investigators.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

The data underscore the need for biomarker testing to identify patients who may be eligible for this therapy, according to physician from Memorial Sloan Kettering Cancer Center.

The drug from AstraZeneca and Ionis Pharmaceuticals demonstrates a sustained benefit through 66 weeks for those with hereditary transthyretin-mediated amyloid polyneuropathy.